ValiRx VAL201 PhaseI/II Trial Progressing In Line With Plan

Mon, 03rd Nov 2014 11:09

LONDON (Alliance News) - ValiRx PLC said Monday that its phase I/II trial of developmental prostate cancer treatment VAL201 is progressing as announced and on schedule with its plan.

The life sciences company has made full details of the trial available on the US National Institutes of Health searchable database as is legally required immediately before application of the trial substance to human beings.

Preliminary outcomes from the first cohort of the trial are expected in the first quarter of 2015.

Shares in ValiRx are trading up 8.6% at 0.380 pence Monday morning.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Related Shares

More News

20 May 2024 16:52

LONDON MARKET CLOSE: London gets boost thanks to rate cut hopes

(Alliance News) - Stock prices in London closed higher on Monday, with investors optimistic that interest rate cuts might be around the corner.

20 May 2024 14:21

ValiRx shares jump as Cytolytix gets Knowledge Transfer Voucher grant

(Alliance News) - ValiRx PLC on Monday noted that the peptide nanoparticle formation Cytolytix received a Knowledge Transfer Voucher grant in conjunct...

16 May 2024 16:29

EARNINGS AND TRADING: Tullow Oil on track to hit free cash flow target

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately report...

15 May 2024 18:38

TRADING UPDATES: Vertu Motors ups dividend as hails record revenue

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

15 May 2024 10:45

AIM WINNERS & LOSERS: Itim up on Majestic Wine contract renewal

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.